Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 7 ( July, 2022 ) > List of Articles

Original Article

Comparison of Serum Nucleosomes and Tissue Inhibitor of Metalloproteinase1 (TIMP1) in Predicting Mortality in Adult Critically Ill Patients in Sepsis: Prospective Observational Study

Nitin Rai, Seema Kashyap, Lokesh Kashyap, Rahul Kumar Anand, Shailendra Kumar

Keywords : Mortality, Nucleosomes, Sepsis, Septic shock, Tissue inhibitor of metalloproteinase1

Citation Information : Rai N, Kashyap S, Kashyap L, Anand RK, Kumar S. Comparison of Serum Nucleosomes and Tissue Inhibitor of Metalloproteinase1 (TIMP1) in Predicting Mortality in Adult Critically Ill Patients in Sepsis: Prospective Observational Study. Indian J Crit Care Med 2022; 26 (7):804-810.

DOI: 10.5005/jp-journals-10071-24258

License: CC BY-NC 4.0

Published Online: 15-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Sepsis is a life-threatening organ dysfunction due to dysregulated host response to infection. Timely identification is important for risk reduction and better outcomes in critically ill patients. Nucleosomes and tissue inhibitors of metalloproteinase1 (TIMP1) are the biomarkers whose validity and utility in predicting organ dysfunction and mortality in sepsis have been proven. However, which biomarker among these two has better predictive value in elucidating disease severity, organ dysfunction, and mortality in sepsis is yet to be answered, and further studies are needed. Methods: Eighty patients with sepsis/septic shock, aged between 18 and 75 years admitted in intensive care unit (ICU) were recruited in this prospective observational trial. Quantification of serum nucleosomes and TIMP1 was done using enzyme linked immunosorbent assay (ELISA) within 24 hours of diagnosis of sepsis/septic shock. The primary outcome was to compare the predictability of nucleosomes and TIMP1 in estimating sepsis mortality. Results: The area under the receiver operating characteristic curve (AUROC) for TIMP1 and nucleosomes to discriminate between survivors and non-survivors were 0.70 [95% Confidence interval (CI), 0.58–0.81] and 0.68 (0.56–0.80), respectively. Although independent, TIMP1 and nucleosomes have statistically significant capacity to discriminate between survivors and non-survivors (p = 0.002 and p = 0.004, respectively), superiority of one biomarker over the other in discriminating between survivors and non-survivors was not observed. Conclusion: The median values of each biomarker showed statistically significant differences between survivors and non-survivors, superiority of one biomarker over other in predicting mortality was not observed. However, this was an observational study and larger studies are needed in the future to validate the findings of this study.

  1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). J Am Med Assoc 2016;5(8):801–810. DOI: 10.1001/jama.2016.0287.
  2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138–150. DOI: 10.1056/NEJMra021333.
  3. Rhee C, Dantes R, Epstein L, Murphy D, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. J Am Med Assoc 2017;318:1241–1249. DOI: 10.1001/jama.2017.13836.
  4. Angus DC, Kelly MA, Schmitz RJ, White A, Popovich J Jr. Caring for critically ill patient. Current and projected workforce requirement for care of critically ill patients with pulmonary disease: can we meet requirements of an ageing population? J Am Med Assoc 2000;284(21):2762–2770. DOI: 10.1001/jama.284.21.2762.
  5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589–1596. DOI: 10.1097/01.CCM.0000217961.75225.E9.
  6. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001;27(Suppl. 1):S33–S48. DOI: 10.1007/pl00003796.
  7. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32(Suppl. 11):S495–S512. DOI: 10.1097/01.ccm.0000143118.41100.14.
  8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95. DOI: 10.1067/mcp.2001.113989.
  9. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 2009;46(1):1–24. DOI: 10.1080/10408360802485875.
  10. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci 2008;1137:180–189. DOI: 10.1196/annals.1448.012.
  11. Ward TH, Cummings J, Dean E, Greystoke A, Hou JM, Backen A, et al. Biomarkers of apoptosis. Br J Cancer 2008;99(6):841–846. DOI: 10.1038/sj.bjc.6604519.
  12. Duplessis C, Gregory M, Frey K, Bell M, Truong L, Schully K, et al. Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsis. J Intensive Care 2018;6:72. DOI: 10.1186/s40560-018-0341-5.
  13. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003;31(7):1947–1951. DOI: 10.1097/01.CCM.0000074719.40109.95.
  14. Chen Q, Ye L, Jin Y, Zhang N, Lou T, Qiu Z, et al. Circulating nucleosomes as a predictor of sepsis and organ dysfunction in critically ill patients. Int J Infect Dis 2012;16(7):e558–e564. DOI: 10.1016/j.ijid.2012.03.007.
  15. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74(2):111–122. PMID: 9352216.
  16. Niño ME, Serrano SE, Niño DC, McCosham DM, Cardenas ME, Villareal VP, et al. TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: multivariate model. PLoS One 2017;12(2):e0171191. DOI: 10.1371/journal.pone.0171191.
  17. Ashoori PY, Liaw P, Toltl L, Webb B, Kilmer G, Carter DE, et al. Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. J Critical Care 2011;26(6):556–565. DOI: 10.1016/j.jcrc.2011.01.008.
  18. Bojic S, Stevuljevic JK, Aleksi A, Gacic J, Memon L, Ogrizovic SS. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis after major abdominal surgery. Dis Markers 2018:5064684. DOI: 10.1155/2018/5064684.
  19. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP1 in severe sepsis. Scand J Infect Dis 2006;38(10):867–872. DOI: 10.1080/00365540600702058.
  20. Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis 2017;9(4):943–945.
  21. Todi S, Chatterjee S, Sahu S, Bhattacharyya M. Epidemiology of severe sepsis in India: an update. Critical Care 2010;14(Suppl. 1):P382. DOI: 10.1186/cc8614.
  22. Mohan A, Shrestha P, Guleria R, Pandey RM, Wig N. Development of a mortality prediction formula due to sepsis/severe sepsis in a medical intensive care unit. Lung India 2015;32(4):313–319. DOI: 10.4103/0970-2113.159533.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.